IRVINE, Calif., – Human Options, Orange County's leading organization in ending the cycle of relationship violence, celebrated its tenth annual "Love Shouldn't Hurt" teen dating conference on February ...

Bio-Rad Laboratories Inc (NYSE:BIO). reported its fourth-quarter 2024 earnings, revealing a slight miss on revenue expectations, with net sales of $668 million compared to a forecast of $681.29 ...

Those interested in scheduling a meeting with Processa management are encouraged to do so through the BIO Partnering portal. For those not attending the conference who are interested in meeting ...

Those interested in scheduling a meeting with Processa management are encouraged to do so through the BIO Partnering portal. For those not attending the conference who are ... s strategy is to develop ...

With our events, we try to create the kind of conference that we would want to attend ourselves, mixing great speakers, insightful content, a forward-thinking outlook and quality networking.

Investors interested in arranging a meeting with the Company’s management during the conference can register on the BIO CEO & Investor ... or Tosymra are safe and effective in children under ...

Can-Fite will participate in a prominent industry event, the BIO CEO & Investor Conference, which provides a platform for visibility and networking with investors and potential partners.

Mazzo, PhD, President and Chief Executive Officer of Lisata, will present a corporate overview at the 2025 BIO CEO & Investor Conference taking place February 10-11, 2025 at the New York Marriott ...

Management is scheduled to give a corporate overview at the BIO CEO & Investor Conference on Tuesday, February 11, 2025 at 10:15 AM EST at the Royale Room and will be available to participate in ...

(“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 2025 BIO CEO & Investor Conference.

BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq ... in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference being held from February 5-6, 2025 in New York.

Switching from ustekinumab to biosimilar SB17 maintains long-term efficacy and safety in psoriasis patients, supporting cost-effective treatment options. A phase 3 trial with 503 participants ...